Liquid Biopsy for Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial aims to see if using blood tests can help start treatment sooner for patients with newly diagnosed lung cancer. The goal is to reduce the time it takes to begin treatment.
Research Team
Nathan A. Pennell
Principal Investigator
Cleveland Clinic, Case Comprehensive Cancer Center
Eligibility Criteria
This trial is for new patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who plan to receive systemic therapy and are referred to the Cleveland Clinic Taussig Cancer Center without prior genetic testing results. It's not open to those who've had previous treatment or adequate molecular testing for their current NSCLC diagnosis.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Liquid Biopsy Testing
Participants undergo liquid biopsy testing to detect cancer cells and actionable genetic markers
Treatment
Participants receive guideline-directed therapy based on liquid biopsy results
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Liquid biopsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Case Comprehensive Cancer Center
Lead Sponsor